A Phase 3 interventional study of Dazukibart in Dermatomyositis and Polymyositis, sponsored by Pfizer. Recruiting at 26 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-25.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
The purpose of this study is to understand how the study medicine, dazukibart, works in people with active idiopathic inflammatory myopathies (dermatomyositis [DM] or polymyositis [PM]).
Idiopathic inflammatory myopathies are a group of disorders that show inflammation of the muscles used for movement. There are several types of idiopathic inflammatory myopathies, including DM and PM.
DM and PM involve weakness of the muscles closest to the center of the body, such as the muscles of the hips, thighs, upper arms, and neck. People with these forms of idiopathic inflammatory myopathies may find it difficult to climb stairs, get up from a seated position, or lift items above their head. People with DM can also have a skin rash.
These disorders negatively impact the quality of life and functioning of patients. In addition to the above, these disorders can affect how the lungs and heart work.
This study is seeking participants who took part in a DM and PM study with dazukibart before. Some participants will receive study medicine, and some participants will not receive study medicine and only complete safety follow-up.
The study medicine will be given as an intravenous (IV) infusion (directly into the veins). This takes about 1 hour, every 4 weeks, from Day 1 to Week 48 (about 12 months) of the study. This will be followed by a safety follow-up period that lasts about 4 months after the last infusion. Participants who receive study medicine will have about 18 study visits at the site over about 16 months.
There will also be participants enrolled in this study who will not receive study medicine. Such participants will only take part in safety follow-up visits as they do not want to or are not eligible to receive dazukibart. These participants will not receive study medicine and will have up to 4 study visits at the site every 4 weeks to complete safety follow-up.
184 studies on the registry are indexed under Dermatomyositis; 63 are open to participants now.
This study's planned enrollment of 211 is above the median of 35 across 130 interventional studies indexed under Dermatomyositis.
Browse Dermatomyositis studies →Pfizer is the lead sponsor of 3,334 studies on the registry; 149 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 391 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive dazukibart via intravenous infusion every 4 weeks.
Drug: Dazukibart
anti-interferon beta therapy
Treatment-Emergent Adverse Events (AEs), Serious AEs, AEs of Special Interest, and AEs leading to treatment discontinuation
An AE is any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. Treatment-emergent are AEs that are absent before treatment or that worsened relative to pretreatment state. Pre-defined AESI for this study are outlined in study protocol.
Time frame: 52 weeks
Number of participants with clinically significant laboratory abnormalities
Clinically significant laboratory abnormalities are those that meet the Common Terminology Criteria for Adverse Events (CTCAE) definition.
Time frame: 52 weeks
Number of participants with clinically significant abnormalities in vital signs
Clinically significant vital sign abnormalities include pulse rate \<40, \>100 or \>120 bpm; systolic blood pressure increase from baseline ≥30 or decrease ≤30 mmHg; diastolic blood pressure increase from baseline ≥20 or decrease ≤20 mmHg.
Time frame: 52 weeks
Number of participants with clinically significant electrocardiogram (ECG) abnormalities
Clinically significant ECG abnormalities include mild (\>450-480 millisecond \[msec\]), moderate (\>480-500 msec or 30-60 msec increase from baseline), and severe (\>500 msec or \>60 msec increase from baseline) QTc prolongation.
Time frame: 52 weeks
Change from baseline in Forced Vital Capacity (FVC)/Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO)
FVC is the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. DLCO is a measure of gas exchange diffusion capacity.
Time frame: 52 weeks
Absolute values and change from baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)
C-SSRS assesses whether participant experienced following: completed suicide (1), suicide attempt (2) (response of "Yes" on "actual attempt"), preparatory acts toward imminent suicidal behavior (3)("Yes" on "preparatory acts or behavior"), suicidal ideation (4) ("Yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior (7)("Yes" on "Has subject engaged in non-suicidal self-injurious behavior").
Time frame: 52 weeks
Change from baseline in Manual Muscle Testing - 8 designated muscles (MMT-8)
Manual Muscle Testing (8 designated muscles) 0 to 150 with higher scores indicating a better outcome
Time frame: 52 weeks
Change from baseline in Physician Global Activity (PhGA)
Physician Global Activity 0 to 10 scale with higher scores indicating a worse outcome
Time frame: 52 weeks
Change from baseline in extramuscular activity or disease activity score and muscle enzyme results
Results come from Total Improvement Score 0 to 100 with higher scores indicating a better outcome and laboratory values
Time frame: 52 weeks
Minimal, Moderate, and Major improvement in Total Improvement Score (TIS) and TIS (continuous) score
Total Improvement Score 0 to 100 with higher scores indicating a better outcome.
Time frame: 52 weeks
Percent change from baseline and change from baseline in Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score (CDASI-A) in DM participants
Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score 0 to 100 with higher scores indicating a worse outcome
Time frame: 52 weeks
Change from baseline in Cutaneous Dermatomyositis Disease Area and Severity Index Damage Score (CDASI-D) in DM participants
Cutaneous Dermatomyositis Disease Area and Severity Index Damage Score 0 to 32 with higher scores indicating a worse outcome
Time frame: 52 weeks
Change from baseline in Patient-Reported Outcomes Measurement Information System - Physical Function (PROMIS-PF)
Patient-Reported Outcomes Measurement Information System - Physical Function 0 to 100 with higher scores indicating a better outcome
Time frame: 52 weeks
Change from baseline in Patient Global Activity (PtGA)
Patient Global Activity 10-point numeric rating scale with higher scores indicating worse outcome
Time frame: 52 weeks
Change from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)
Health Assessment Questionnaire-Disability Index 20 questions with 0 to 3 scale where higher scores indicate a worse outcome
Time frame: 52 weeks
Change from baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)
Functional Assessment of Chronic Illness Therapy - Fatigue 0 to 52 with higher scores indicating a better outcome
Time frame: 52 weeks
Change from baseline in EuroQoL 5 Dimensions (EQ-5D-5L) and EuroQoL Visual Analog Scale (EQ-VAS)
EuroQoL 5 Dimensions and EuroQoL Visual Analog Scale with higher scores indicating a worse outcome
Time frame: 52 Weeks
Change from baseline in Healthcare Resource Utilization Questionnaire (HRU)
Healthcare Resource Utilization Questionnaire measures the healthcare utilization burden while on treatment
Time frame: 52 weeks
Change from baseline in 5-D Itch Scale Score in DM participants
5-D Pruritis Scale 5 to 25 with higher scores indicating a worse outcome
Time frame: 52 weeks
Change from baseline in corticosteroid (CS) and non-steroid immunosuppressant/immunomodulator and antimalarial dose
CS and non-steroid immunosuppressant/immunomodulator and antimalarial dose
Time frame: 52 weeks
Response in CS and non-steroid immunosuppressant/immunomodulator and antimalarial tapering
CS dose ≤5 mg/day or CS and non-steroid immunosuppressant/immunomodulator and antimalarial free
Time frame: 52 weeks
Rescue therapy use assessment
Rescue therapy received during the study and number of cycles
Time frame: 52 weeks
Auto antibodies and immunogenicity presence
Auto antibody lab assessment (eg. TIF1-γ/P155, NXP2/P140, SAE, JO-1 and MDA-5) and ADAs/Nabs
Time frame: 52 weeks
Not enrolling at this site — choose another above.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dazukibart